|
Adenoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Wnt/Tcf, Lgr5, Ascl2 and/or Bmi1 signalling is believed to define the mouse intestinal stem cell niche(s) from which adenomas arise.
|
22637696 |
2013 |
|
Adenoma of large intestine
|
0.010 |
Biomarker
|
disease |
BEFREE |
In the Immunotherapy Study, fewer colon adenomas tended to be observed in recMASH2+AS15-treated mice (4.1 [2.9-6.0]) compared to controls (AS15 4.7 [3.3-6.6]; PBS 4.9 [3.5-6.9]; no significant difference). recMASH2+AS15 induced MASH2-specific antibody and CD4+ responses in both mouse models. recMASH2+AS15 partially protected mice against MASH2-expressing tumors and reduced spontaneous colorectal adenomas in Apc+/Min-FCCC mice, indicating that MASH2/HASH2 antigens are targets for colorectal cancer immunotherapy.
|
30682058 |
2019 |
|
Anoxia
|
0.010 |
AlteredExpression
|
phenotype |
LHGDN |
In this study, we found that trophoblast nuclear protein binding to these E boxes declined with syncytiotrophoblast differentiation in 20% O(2) and was induced by hypoxia; however, Mash-2 did not appear to bind to any of these E boxes.
|
12917334 |
2003 |
|
Autoimmune Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
In conclusion, our results indicate that abnormal Tfh cell differentiation via Ascl2 regulation might contribute to the pathogenesis of autoimmunity.
|
31539517 |
2019 |
|
Autoimmune Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
Ascl2 (achaete-scute complex homologue 2), identified as a homologue of the Drosophila achaete-scute gene, has been shown to play an essential for the pathogenesis of autoimmune diseases and cancers.
|
30722992 |
2019 |
|
B-Cell Lymphomas
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Overexpression of Ascl2 also increased the expression of proinflammatory cytokines and chemoattractants including interleukin 6 (IL-6), tumor necrosis factor-α, IL-8, programmed cell death 1 (PD-1), IL-21, and B-cell lymphoma 6 (Bcl-6).
|
28728856 |
2017 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Altogether, our study suggests that ASCL2 defines a subgroup of highly progressive breast cancer and serves as a marker to evaluate the risk of cancer relapse.
|
28469967 |
2017 |
|
Cancer Relapse
|
0.010 |
Biomarker
|
disease |
BEFREE |
Altogether, our study suggests that ASCL2 defines a subgroup of highly progressive breast cancer and serves as a marker to evaluate the risk of cancer relapse.
|
28469967 |
2017 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The enhanced WiNTRLINC1/ASCL2/c-Myc axis involved in Wnt pathway activation is a common pathway essential for differentiated colon tumorigenesis, especially with young onset, and may be essential for a viable phenotype of colon cancer.
|
31549316 |
2019 |
|
Carcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Therefore, we investigated dimethylation of histone H3 at lysine 4 (H3K4diMe) and H3K4 methylating (Ash2 complex) and demethylating enzymes (LSD1) in carcinomas of the hepatic and gastrointestinal tract.
|
19896696 |
2010 |
|
Choriocarcinoma
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
Negative expression of HASH2 in CM but positive expression in malignant tumors suggests the presence of a specific mechanism for inactivation of the HASH2 gene in CM and reactivation in IvM or ChCa.
|
17165436 |
2006 |
|
Colitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Notably, lentivirus-mediated overexpression of Ascl2 remarkably alleviated the severity of 2,4,6-trinitrobenzenesulfonic acid solution (TNBS)-induced colitis in mice, with decreased level of colonic IL-17A.
|
30722992 |
2019 |
|
Colon Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
The transcription factor Ascl2 (Wnt target gene) is fate decider of intestinal cryptic stem cells and colon cancer stem cells.
|
29886802 |
2018 |
|
Colon Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
However, its involvement in colon cancer and downstream molecular events is largely undefined; in particular, the mechanism by which Ascl2 regulates the plasticity of epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) programs in colon cancer cells remains unknown.
|
25371200 |
2014 |
|
Colon Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
The intestinal stem cell regulating gene ASCL2 is required for L1-mediated colon cancer progression.
|
29551399 |
2018 |
|
Colon Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Ascl2 activation by YAP1/KLF5 ensures the self-renewability of colon cancer progenitor cells.
|
29312609 |
2017 |
|
Colon Carcinoma
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
WiNTRLINC1 was not significantly associated with prognostic factors in colon cancer and other lncRNAs, while the WiNTRLINC1/ASCL2/c-Myc signatures were unique to young-onset colon cancer with differentiated histology.
|
31549316 |
2019 |
|
Colonic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Global gene expression analysis of rat colon cancers induced by a food-borne carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.
|
15059925 |
2004 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These data suggest that 74-85% of colorectal cancers express a Lgr5/Ascl2 associated signature and support the hypothesis that they derive from Lgr5(+)/Ascl2(+) crypt stem cells, not Bmi1(+) stem cells.
|
22637696 |
2013 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest that the Ascl2/CDX2 axis may serve as a potential therapeutic target in colorectal cancer.
|
26307678 |
2015 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, our study demonstrated that Ascl2, a fate decider of CRC progenitor cells can be activated by the Hippo signaling pathway in CRC progenitor cells, and ensured their self-renewability.
|
29312609 |
2017 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ASCL2 was identified as a causative gene involved in therapeutic resistance against anticancer treatments in CRC.
|
30706227 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
WiNTRLINC1 is a long non-coding RNA (lncRNA) that positively regulates the Wnt pathway via achaete-scute complex homolog 2 (ASCL2) in colorectal cancer.
|
31549316 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the involvement of ASCL2, a Wnt target gene and key determinant of intestinal stem cell state, in L1-mediated CRC progression.
|
29551399 |
2018 |
|
Colorectal Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
SNAIL1 combines competitive displacement of ASCL2 and epigenetic mechanisms to rapidly silence the EPHB3 tumor suppressor in colorectal cancer.
|
25277775 |
2015 |